Newsroom | 49685 results

LONDON--(BUSINESS WIRE)--Automata, the lab automation company building fully integrated, AI-ready platforms for life sciences, today announced the close of a $45 million Series C funding round led by Dimension with participation from Danaher Ventures, Tru Arrow Partners, Octopus Ventures, Entrepreneurs First, and others. The round also includes a strategic investment partnership with Danaher Corporation, with Murali Venkatesan Ph.D., Global Head of Danaher Ventures and Vice President of Science...

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced the final results of its voluntary self-tender offer to purchase 300,000 shares of its common stock, par value $0.001 per share (“Common Stock”), which expired one minute after 11:59 p.m., New York City time, on January 26, 2026. Based on the fi...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Teams Up with Former Professional Quarterback Tony Romo on ‘Highlights REAL’ Campaign...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that its subsidiary, Akos Biosciences, has licensed to TOTEC Pharma, Inc. (“TOTEC”) its US Trademark portfolio for RCANN™ and an RCANN™ design. TOTEC, an affiliate of Aries Science & Technology (“Aries”), is advancing the commercializati...

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that the U.S. Food & Drug Administration (FDA) has accepted for filing Summit's Biologics License Application (BLA) seeking approval for ivonescimab in combination with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) post-tyrosine kinase inhibitor (TKI) therapy. The FDA...

MARKHAM, Ontario--(BUSINESS WIRE)--Exact Imaging, a global leader in high-resolution micro-ultrasound systems for prostate cancer, today reported strong business momentum in calendar year 2025, reflecting progress across commercial execution, clinical validation, and market adoption. During the year, the company implemented a new sales model, expanded the clinical evidence supporting micro-ultrasound–guided prostate imaging, achieved inclusion in leading clinical guidelines, and added new custo...

TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced the appointment of Antoinette Paone as Chief Development Officer (“CDO”) and Head of Regulatory Affairs. Ms. Paone brings extensive experience leading regulatory strategy from clinical development through approval, including her work on Kalydeco and Orkambi at...

BARCELONA, Spain--(BUSINESS WIRE)--Almirall, S.A. (ALM) a global pharmaceutical company dedicated to medical dermatology announced today that China’s National Medical Products Administration (NMPA) has approved Seysara® (sarecycline hydrochloride). Sarecycline hydrochloride is the first oral antibiotic that was specifically developed for use in acne and is approved for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older1. Ac...

LONDON & SEATTLE--(BUSINESS WIRE)--Tenpoint Therapeutics, Ltd., a global, commercial biotechnology company focused on developing groundbreaking treatments to improve vision in the aging eye, today announced that the U.S. Food and Drug Administration (FDA) approved YUVEZZI™ (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, previously known as BRIMOCHOL™ PF, the first and only dual-agent eye drop for the treatment of presbyopia in adults. Presbyopia, the gradual loss of near vi...

HEIDELBERG, Germania e CAMBRIDGE, Massachusetts--(BUSINESS WIRE)--Novaliq, un'azienda biofarmaceutica specializzata in terapie oculari di prima classe e all'avanguardia basate sulla sua esclusiva categoria di farmaci EyeSol® senza acqua, ha annunciato oggi che la Food and Drug Administration (FDA) statunitense ha approvato la candidatura come nuovo farmaco sperimentale (IND) per NOV05, il primo IND dell'azienda per il trattamento delle malattie dell'occhio interno. Il testo originale del presen...